Electromed (ELMD)
Prescription SmartVest airway-clearance systems with direct homecare reimbursement and support.
Something off on this page? Send us feedback.
Designs and directly supports prescription SmartVest airway-clearance systems, converting clinician referrals into payer-billed homecare deliveries, training, and follow-up. Revenue is concentrated in U.S. homecare and one product franchise, tying operations to reimbursement, referrals, regulatory compliance, and supplier-backed assembly.
Designs, assembles, and supports the prescription-only SmartVest Airway Clearance System, including SmartVest Clearway and SmartVest SQL models. The HFCWO system uses an air-pulse generator, garment, and hose to mobilize retained secretions for patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions. Most activity is U.S. homecare, with limited international distributor sales.
Generates most revenue by taking clinician referrals through documentation and insurance authorization, payer billing, delivery, in-home training, and follow-up rather than relying chiefly on home-medical-equipment distributors. Final assembly, testing, and shipment approval occur in New Prague while suppliers make components to its specifications. The business depends on prescription referrals, payer coverage and collection, FDA quality requirements, patient-data obligations, and a single SmartVest product franchise.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Aug 26, 2026 | Morgan Stanley | Target | $50 | |
| Aug 26, 2026 | Lake Street | Reiterate | Buy | $47 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $20.5M · Total debt $133.0K · Total assets $66.3M · Shareholders' equity $54.0M
- Revenue
- $19.4M
- Operating income
- $3.8M
- Net income
- $3.4M
No dividends on record.
| Institutions131 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 56.21% | 4.65M shares | |
| Insiders4 holders · as of Jul 11, 2022 | 25.51% | 2.11M shares | |
| Otherremainder | ≈ 18.28% | 1.51M shares |
8.28M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Dr. George H. WinnInsider | 7.34% | 607,891 | 13G/Afiled Jan 14, 2019 ↗ |
H. CraneyInsider | 6.67% | 551,901 | 13D/Gfiled Dec 12, 2018 ↗ |
J.E. Simmons & Co., P.C.Institution | 5.84% | 483,822 | 13Fas of Jun 30, 2026 |
Kathleen S. SkarvanInsider | 5.76% | 477,312 | 13Dfiled Jul 11, 2022 ↗ |
Bradley L. RadoffInsider | 5.74% | 475,000 | 13Gfiled May 26, 2022 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Baxter International
HFCWO airway-clearance rival across homecare and acute-care settings.
- Philips (ADR)
Home HFCWO rival with direct patient support and HME distribution.
- Tactile Medical
Portable wearable HFCWO rival in home airway clearance.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Electromed | $28.33 | +4.54% | $233.8M | 21.6 | 19.5 | 3.2 | +11.6% |
| Baxter International | $25.61 | −0.31% | $13.29B | — | 12.2 | 1.2 | +5.3% |
| Philips (ADR) | $26.27 | −0.44% | $25.77B | 19.6 | 13.5 | 1.3 | −2.9% |
| Tactile Medical | $22.41 | +0.72% | $505.5M | 20.7 | 19.7 | 1.4 | +8.6% |
| Median | 20.2 | 13.5 | 1.3 | +5.3% |